



Article  (Published Version)
http://sro.sussex.ac.uk
Davies, Geoff, Csecs, Jenny L L, Ball, Heather, Dare, Jess, Bremner, Stephen, Hosking, Robin, 
Critchley, Hugo D, Grey, Nick and Eccles, Jessica A (2021) Altering Dynamics of Autonomic 
Processing Therapy (ADAPT) trial: a novel, targeted treatment for reducing anxiety in joint 
hypermobility. Trials, 22 (1). a645 1-10. ISSN 1745-6215 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/102224/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
STUDY PROTOCOL Open Access
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Therapy (ADAPT) trial: a novel, targeted
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Abstract
Background: Hypermobility is a poorly recognised and understood musculoskeletal disorder thought to affect
around 20% of the population. Hypermobility is associated with reduced physiological and psychological
functioning and quality of life and is a known risk factor for the development of an anxiety disorder. To date, no
evidence-based, targeted treatment for anxiety in the context of hypermobility exists. The present intervention
(ADAPT—Altering Dynamics of Autonomic Processing Therapy) is a novel therapy combining bio-behavioural
training with cognitive approaches from clinical health psychology targeting the catastrophisation of internal
sensations, with aim to improve autonomic trait prediction error.
Method: Eighty individuals with diagnosed hypermobility will be recruited and the efficacy of ADAPT to treat
anxiety will be compared to an Emotion-Focused Supportive Therapy (EFST) comparator therapy in a randomised
controlled trial. The primary treatment target will be post therapy score on the Beck Anxiety Inventory, and
secondary outcomes will also be considered in relation to interoception, depression, alexithymia, social and work
adjustment, panic symptoms and dissociation. Due to COVID restrictions, the intervention will be moved to online
delivery and qualitative assessment of treatment tolerance to online therapy will also be assessed.
Discussion: Online delivery of an intervention targeting anxiety would improve the quality of life for those
experiencing anxiety disorder and help to reduce the £11.7 billion that anxiety disorders cost the UK economy
annually.
Trial registration: World Health Organization ISRCTN17018615. Registered on 20th February 2019; trial protocol
version 2
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Introduction
Hypermobility is a poorly-recognised and understood
musculoskeletal disorder [1], affecting approximately 20%
of the population [2]. Hypermobile individuals are more
likely to experience severe chronic widespread pain and
have co-morbid rheumatic conditions (60%) [3] and dys-
autonomia [4]. Generally, musculoskeletal disorders are
associated with impairments in physical, psychological
functioning and health-related quality of life [5] and work
functioning [6]. Therefore, the burden on quality of life
can be substantial in those with hypermobility [7].
Symptomatic hypermobility is more prevalent, but less
well-recognised and treated than inflammatory and
other arthritides [1], accounting for up to 45% of general
rheumatology outpatient referrals (estimated 900,000 at-
tendances in 2014–2015 in England [8]). A quarter of
patients attending rheumatology clinics experience anx-
iety, higher than rates in other medical clinics [9]. In line
with this, hypermobility is a risk factor for development
[10] and presence of anxiety/panic (OR 4.39, OR 6.72)
[11]. This association has long been recognised [10–12].
The health economic impact of hypermobility and anx-
iety is unknown, but direct cost of anxiety disorders
alone in the UK is £11.7 billion [13]. As such, given the
associated impairments people with musculoskeletal dis-
orders experience, it is likely experiencing hypermobility
and anxiety comorbidly may cost the UK a significant
amount of money if adequate treatments are not found
and many people with hypermobility may continually
struggle with anxiety.
Intervention recommended for generalised anxiety dis-
order and panic disorder in adults is generally based on
the principles of cognitive behavioural therapy (CBT)
due to its associated effectiveness [14, 15]. First, people
should be educated about these disorders and offered
self-help materials and/or psychoeducational groups.
Where these do not lead to improvement, formal psy-
chological therapies should be offered: CBT or applied
relaxation for generalised anxiety disorder and CBT for
panic disorder [15]. Suggestions have been made that
CBT may help people with hypermobility develop effect-
ive coping strategies, which can be linked to managing
chronic pain [16], and work on cognitive distortions
[17]. One pilot study used a multidisciplinary rehabilita-
tion programme combining physical and cognitive-
behavioural therapy for people with Ehlers-Danlos Syn-
drome/Joint Hypermobility Syndrome (n = 12) and
found significant changes in perceived performance of
daily activities and self-perceived pain [18], but impact
on anxiety was not considered.
To date, no targeted treatments of anxiety exist for
people with hypermobility. The brain-body mechanisms
underlying this association have been explored in
previous research [19] and characterise these by aberrant
autonomic control and central representation (i.e. auto-
nomic trait prediction error). These mechanisms are
grounded in theoretical models [20, 21] and offer a novel
target for a pioneering interventional trial (proof of con-
cept), providing deeper insight into psychophysiological
mechanisms of anxiety and its alleviation in hypermobil-
ity, helping fill a substantial knowledge and service gap.
Data will be used to support future funding bids, with
associated impact on patient choice of intervention.
Choice of comparators
Given the evidence described for treating anxiety with cog-
nitive behavioural principles, ADAPT (Altering Dynamics
of Autonomic Processing Therapy) will combine cognitive
approaches from clinical health psychology with bio-
behavioural training (i.e. interoceptive training based on the
work in [20]). This work will target catastrophisation of in-
ternal sensations [22] and train participants to more accur-
ately perceive their own heartbeats to reduce autonomic
trait prediction error (i.e. to increase correspondence be-
tween measured changes in heart rate and subjective judge-
ment of these changes) respectively. This active
intervention will be compared to a control therapy which
replicates therapist contact but is not focussed on intero-
ception or cognitive behavioural approaches, i.e. emotion
focussed supportive therapy (EFST). Past evidence suggests
that EFST can lead to improvements in anxiety [23].
Objectives
The primary objective of this study is to assess the effi-
cacy of ADAPT. We hypothesise that participating in
ADAPT will lead to significantly reduced anxiety and
improvement compared to EFST.
Method
Trial design
The design is a randomised controlled trial comparing
two non-drug therapies for anxiety in hypermobility
(ADAPT vs. EFST). Participants will be blind to the
therapy condition they will be in. SPIRIT reporting
guidelines [24] have been used throughout this paper.
Participants
Participants will be recruited from the UK via online ad-
vertising and will be 18 years old or over and have lived
experience of both joint hypermobility (score ≥ 2 on the
hypermobility self-report questionnaire OR a hypermo-
bility related diagnosis: Joint Hypermobility Syndrome
[JHS], Hypermobility Spectrum Disorder [HSD], Ehlers-
Danlos Syndrome [EDS]) and anxiety (score > 15 on the
Beck Anxiety Inventory [BAI]). They will be free of other
major psychiatric disorders except comorbid depression.
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Full inclusion and exclusion criteria are available in
Table 1. Stable dose of medication (three months with-
out change) and not currently receiving another form of
talking therapy are inclusion criteria adopted to increase
the validity of possible findings related to the non-drug
therapies used.
The research team will contact interested partici-
pants and send them a participant information sheet
(PIS). If happy to proceed, a telephone screening will
take place to establish if the participant has met the
inclusion criteria, and then participants will be re-
ferred to a research psychologist to obtain informed
consent and conduct the full study assessment mea-
sures, in combination with the research assistant (see
Table 2 for full list of measures). Those who do not
meet the criteria will be informed sensitively and re-
ferred on to other services where clinically appropri-
ate. General practitioner (GP) details will be noted
during assessment and they will be informed about
participation for those eligible.
Interventions
Two trained clinical psychologists will deliver both inter-
vention arms in order to minimise potential effect of in-
dividual therapist. Patients in both intervention groups
will receive 8 sessions lasting up to 90min in duration
(12 h total). These sessions will be completed weekly
where possible.
Emotion-Focused Supportive Therapy (EFST)
EFST is a manualised, non-directive therapy focusing on
the emotional experience of the participant and the link
emotions may have to events in their life. The interven-
tion focuses on building a safe therapeutic relationship,
summarising, labelling and exploring emotions in ses-
sions. Participants can freely choose what is to be cov-
ered in each session as it is a non-directive therapy. To
control for the confound of homework in the ADAPT
intervention arm, participants will also complete weekly
homework diaries listing emotional responses to events
in the week to be potentially discussed in the subsequent
session. As a comparator therapy, the intervention does
not include cognitive appraisals or direct participants to
the symbiotic relationship between thoughts and behav-
iours. EFST will not involve any interoception training.
Altering Dynamics of Autonomic Processing Therapy
(ADAPT)
Expert collaborators recommended combining cognitive
approaches from health psychology (targeting catastro-
phisation of internal sensations [22, 41, 42] with bio-
behavioural training to reduce autonomic trait prediction
error (i.e. to increase correspondence between measured
changes in heart rate and subjective judgement of these
changes). Cognitive behavioural principles will be used
to address anxiety through structured sessions, problem
identification, formulation and behavioural experiments.
Sessions will focus on addressing beliefs and appraisals
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age Adults aged 18 years or over Participants under the age of 18
Capacity All participants must be able to give informed consent Unable to give informed consent
Joint
hypermobility
Diagnosis of hEDS/HSD/JHS OR
Score of 2 or more on 5-point questionnaire to detect joint
hypermobility
No diagnosis of hEDS/HSD/JHS AND score of 1 or less on 5 point
questionnaire to detect joint hypermobility
Anxiety Self-reported lived experience of anxiety disorder AND
A score of 16 or more on Beck Anxiety Inventory endorsing
moderate anxiety level AND
Anxiety should be the primary psychiatric problem
No self-reported lived experience of anxiety disorder OR
A score of 15 or less on Beck Anxiety Inventory
OR




No presence of major psychiatric disorder, except co-morbid
depression
Presence of major psychiatric disorder (other than co-morbid de-
pression), e.g. bipolar affective disorder, schizophrenia or psychosis
OR personality disorder (e.g. emotionally unstable personality dis-
order) OR diagnosed neurodevelopmental disorder such as atten-




All participants should be on a stable dose of medication for 3
months OR
Medication free AND willing to consider omitting medication
that directly affects heart rate (e.g. beta blockers) during the
trial
Not on a stable dose of medication (or medication free) for 3
months
Language All participants must have a reasonable level of both written
and spoken English as therapies and assessments will be
conducted in English
Poor level of both written and spoken English
Therapy Not receiving another modality of talking therapy Currently receiving another modality of talking therapy
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around anxiety and safety seeking behaviours, imagery
rescripting and homework tasks to be completed be-
tween sessions adapted from (Clark, Salkovskis et al.
1999). Participants will be allocated to one of four proto-
cols detailed below (Table 3). Therapists will review
homework tasks with participants weekly to assess pro-
gress and intervention adherence. Interoception training
will be conducted in five of the therapy sessions. Intero-
ception training will be completed via a MATLAB plat-
form on a laptop and will require participants to wear a
pulse oximeter (NONIN), which will enable their heart-
beats to be recorded. Interoception training will involve
two tasks: heartbeat tracking and heartbeat discrimin-
ation [29]. In heartbeat tracking, participants will be
asked to count their heartbeats across a period of time
across 6 trials (range 10–50 s). Participants will start
using ‘set B’ with trials in duration between 10 and 25 s.
If the participants get 4 trials correct (within 3 beats of
the actual answer), they change sets to ‘set A’ with trials
25–50 s in duration. If participants get 4 trials 5 beats or
more out on set A, they reduce the next training set
back to set B. In heartbeat discrimination, participants
will be played their real heartbeat (10 beats); however,
the task randomly introduces a delay of 300 ms in some
of the trials. Participants will have to decide if the heart-
beat they hear is in or out of sync with their actual
heartbeat. Participants will complete 20 trials of the
heartbeat discrimination task. After each trial, partici-
pants will be asked to make a confidence judgement on
their response on a visual analogue scale ranging from 0
(not at all confident) to 100 (extremely confident). Par-
ticipants will be informed after each trial the actual
number of heartbeats in the trial or whether the tone
was in or out of sync with their actual heartbeat. They
will then exercise for 2 min to raise their heart rate and
repeat both heartbeat tracking and heartbeat discrimin-
ation tasks.
Outcome
Anxiety is the primary outcome, which will be measured
by the BAI and group comparisons of mean scores from
baseline assessment to end of therapy will be made. Sec-
ondary outcomes are as follows: autonomic trait predic-
tion error, interoceptive trait prediction error, presence
or absence of psychiatric disorder measured by the MINI
[27], the GAD-7 ([43] an additional anxiety measure),
depression measured by the PHQ-9 [32], functioning
measured by the Work and Social Adjustment Scale
[33], anxiety sensitivity quantified by the Anxiety Sensi-
tivity Index [35], alexithymia (i.e. difficulty describing
one’s emotions) measured by the Toronto Alexithymia
Scale-20 [36], dissociation quantified by the Dissociative
Table 2 Study assessment measures
Questionnaires Research assistant led Research psychologist led
Pain and fatigue visual
analogue scales [25, 26]
Autonomic assessment Mini International
Neuropsychiatric Interview
(MINI [27])
BAI [28] Interoception assessment [29] Psychological assessment
Generalised Anxiety Disorder-
7 (GAD-7 [30])
Hypermobility assessed using the Brighton Criteria for joint hypermobility syndrome
and 2017 Hypermobile Ehlers-Danlos Syndrome (hEDS) Criteria [31]
Patient Health Questionnaire-
9 (PHQ-9 [32])
Work & Social Adjustment
Scale [33]














Quality of Life Score [40]
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Experiences Scale [37] and current panic symptoms
measured by the Panic Disorder Severity Scale [38] (see
more information on measurement in Table 4). All sec-
ondary outcome assessment (except the MINI and feasi-
bility measures) will involve analysing change scores on
the measures listed from baseline assessment to end of
therapy. The MINI will involve comparing the number
of psychiatric disorder presentations from baseline as-
sessment to end of therapy. Trained clinical psycholo-
gists will complete psychological interview assessments
(including the MINI) and a trained research assistant
will complete research assessments.
Feasibility and acceptability of the interventions will be
assessed. Qualitative semi-structured interviews, with
the research assistant, and completion of the Satisfaction
with Therapy questionnaire [46] post-therapy will be
completed to assess intervention tolerance, the practic-
ability of the interventions (e.g. including Likert scale
questions about whether they found the interoception
application simple to use) and tolerance to therapy—
questions will include what participants liked and dis-
liked about the intervention they received. Answers in
the semi-structured interview and on the questionnaire
will be compared across therapy conditions. Further as-
sessment of tolerability will be completed by comparing
the number of people who complete therapy and the
number of people who withdraw. Reporting of adverse
side effects will be compared across conditions as an
additional measure of acceptability. Missing data will be
quantified (item, instrument and overall assessment
level) (which will include participants who withdraw)
and used as a measure of acceptability. Completion of
homework will be compared across therapy conditions
to determine whether there is a difference between how
acceptable this appeared in each intervention. Ease of re-
cruitment will be ascertained by calculating the ratio of
Table 3 Therapy protocol session plan










formulation, psychoeducation, socialise to






Interoception training Interoception training Interoception training Interoception training




Panic diary in formulation, SSB,
downward arrow for threat beliefs,
selective attention training
Review between session work, identify
safety behaviours and avoidance,
observer vs. field perspective, attention
training
Review homework,
socialising to model, belief
identification, theory A/
theory B





Review formulation, BE relating
to feared symptoms, symptom-
induction, review BE and beliefs,
theory A/theory B
Manipulation of self-focused attention,
plan and do BE (video/audio).
Review beliefs and SSB,
threat versus coping, plan BE





BE, review beliefs, verbal
reattribution, theory A/theory B
BE feedback review, prediction versus





Five Introduction of the
worry tree, imagery re-
scripting.
BE, review beliefs Review BE and beliefs, survey work Review BE, review goals
and formulation, plan BE,
imagery re-scripting
Interoception training Interoception training Interoception training Interoception training
Six Continue BE, surveys
and imagery work
continued
BE, review beliefs and imagery Widening the bandwidth experiments,
review BE




Seven Continue BE and
exploration of beliefs in
relation to cognitive
formulation
BE, reappraise beliefs, imagery
re-scripting
Review BE, imagery re-scripting, func-
tion of worry and rumination, BE
Review BE, imagery re-
scripting
Interoception training Interoception training Interoception training Interoception training
Eight Conclusion of therapy,
review goals, relapse
prevention
Conclusion of therapy, review
goals, relapse prevention





GAD generalised anxiety disorder, BE behavioural experiment, NOS not otherwise specified, SSB safety seeking behaviours
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contacts to the study to the number of participants who
are subsequently eligible for and who consent to
intervention.
Sample size
Eighty is the required sample size. Based on previous ex-
perimental data (mean anxiety levels in hypermobile
subjects BAI = 24.5 [sd 9.36]), this sample size is pow-
ered (90% power, 0.05 α) to detect a clinically meaning
difference on BAI of 7.5 points (34 participants per
group). Thirty-five people per group is the recom-
mended sample size, based on estimating the standard
deviation of the primary outcome with good precision
[20], to obtain good quality data to inform planning of a
future definitive trial. Studies conducted by JAE indicate
an attrition rate of approx. 14%; thus, the sample size of
40 per group will take this into account. No further
follow-up measures will be obtained if a participant
withdraws from the study.
Recruitment
Participants will primarily be identified through ethically
approved advert. Adverts will be displayed at clinical
sites and distributed via electronic and paper messaging
boards/newsletters to potential participants, e.g. research
small ads at University of Sussex and Facebook/Twitter
accounts/newsletters of relevant patient/research organi-
sations (e.g. via Brighton and Sussex Medical School
[BSMS] and partner universities, by funder (MQ:
Transforming Mental Health), and by patient organisa-
tions (e.g. Hypermobility Syndromes Association, Ehlers-
Danlos Support UK). Electronic advertisement will use
geo-targeting to the Sussex and wider South East area
where possible. Potential participants will also be identi-
fied using the Sussex Partnership NHS Foundation Trust
Research Network.
All further contact with potential participants will be
via phone, email and post as described below and per
potential participant preference.
Interested participants responding to the advert will
then contact the research team (email/phone) and be
sent (email/post) an appropriate for phase PIS inviting
them to contact the research team (email/phone) for
further information. A trained member of the re-
search team will then conduct a basic telephone
screening to check if potential participants meet
inclusion criteria for the study. Participants deemed
eligible to take part in the study will subsequently be
invited to take part in the study assessment by a
study clinical psychologist. A trained research assist-
ant or a member of the research team will collect in-
formed consent from participants prior to undergoing
assessment.
The research team will sensitively inform participants
if they do not meet the criteria and give an explanation.
They will be signposted to relevant support organisa-
tions as appropriate and reassured that their routine
clinical care will not be affected in any way.




Primary outcome Anxiety levels (BAI) [28]
Secondary
outcomes
Autonomic trait prediction error (calculated by z- transforming the mean proportional rise in heart rate on active stand
[orthostasis] and subtracting the z-transformed orthostatic sub-scale of the Autonomic Symptoms of Quality of Life Score [40] for
each participant)
Interoceptive trait prediction error (i.e. the mismatch between objective interoceptive accuracy and subjective interoceptive
sensibility [44]) will be calculated using the difference between interoceptive sensitivity (i.e. accuracy) and sensibility.
Interoceptive sensibility and interoceptive sensitivity scores will be z-transformed and one subtracted from the other.
Interoceptive sensitivity score will be calculated across the heartbeat tracking trials at assessment using this equation [44, 45]:
1 - jnbeatsreal−nbeatsreported jðnbeatsrealþnbeatsreported=2Þ
for heartbeat discrimination trials, this will be calculated by: number of correct trials / number of total trials in assessment
Interoceptive sensibility will be assessed using the total score from the Body Perception Questionnaire [39].
Presence/absence of psychiatric disorder as evidenced by the MINI [27]: Major depressive episode, panic disorder, agoraphobia,
social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder and generalised anxiety disorder
Psychiatric symptomatology as evidenced by scores on the:
1. GAD-7 [43]
2. PHQ-9 [32]
3. Work and Social Adjustment Scale [33]
4. Anxiety Sensitivity Index [35]
5. Toronto Alexithymia Scale-20 [36]
6. Dissociative Experiences Scale [37]
7. Panic Disorder Severity Scale [38]
Feasibility and acceptability measures of RCT (e.g. practicability, tolerability, Satisfaction with Therapy questionnaire [46])
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Treatment allocation and blinding
Participants will be allocated to either ADAPT or EFST
through the online randomisation service sealed enve-
lope [47]. Minimisation with a random element (80%
probability of being allocated to the arm which mini-
mises imbalance) will be utilised, and participants will be
additionally stratified by gender and anxiety score (BAI
≤ 25 vs. > 25). Allocation sequence will not be visible to
the psychologists delivering the therapy. Allocation con-
cealment will occur until the participant has been deter-
mined eligible for the intervention and sealed envelope
reveals to the psychologists which intervention partici-
pants have been allocated. Therefore, randomisation will
be conducted without any influence of the study team.
Psychologists will not be blind to intervention group,
due to the nature of the intervention. Whilst they will
not reveal to the participant whether the therapy is
ADAPT or EFST, due to the nature of the interventions,
it is possible participants will not be completely blinded
to allocation. A research assistant will be blinded to con-
dition when assessing intervention outcome and ques-
tionnaires will be completed without involvement from
researchers.
Data collection
The principal investigator will train the clinical research
coordinators, research psychologists and research assist-
ant in data collection, entering, coding and checking as
appropriate. Data will be pseudonymised using partici-
pant ID. Psychologists will access weekly process data
collected prior to therapy sessions starting. The study
team will access data using a secure login. Members of
the study team will collect interoception data and access
this securely. The trained research assistant will assess
objective signs of orthostatic intolerance by using a fin-
ometer (SMART MEDICAL). Where source data are
collected on paper, including the hypermobility (at base-
line) and MINI assessments (at baseline and end of
intervention), an exact copy of the anonymised data will
be manually input into the trial database by a named
member of the study team. The research assistant will
code all data except treatment allocation group which
will be entered by the principal investigator.
Participants will be reimbursed £20 and £25 at the
start and end of therapy respectively for completion of
trial assessments and to aid retention.
Dropout from the study will be recorded, including
reasons where given. Participants are free to withdraw at
any point during the study and can request their previ-
ously collected data not to be used. Withdrawal or de-
clining to participate will not affect their NHS care in
any way; participants are informed of this in the partici-
pant information sheet. Participants may be withdrawn
from the intervention if their clinical presentation
changes in relation to exclusion criteria (e.g. being
started on beta-blocker medication, as this could con-
found the results) or if their clinical condition requires
urgent other treatment (e.g. if the participant develops a
psychotic disorder). Withdrawn participants will not be
replaced.
Data management
The study team will treat participant information with
confidentiality at all times. They will anonymise data
held on records and password-protected databases, as-
sign participant ID numbers, and be fully compliant with
the General Data Protection Regulation and the Data
Protection Act when handling and storing data. There-
fore, personal information will be kept separate from the
trial data. All members of the research team and other
individuals from collaborating trusts or universities in-
volved in collecting, inputting, processing, using and
sharing data will have had Information Governance
Training. Data management will be a standard item on
the agenda for both research team and steering group
meetings. Behavioural data will be collected on password
protected computers and stored in link-anonymised data
files. All data will be backed up to a central storage facil-
ity automatically, related to the University of Sussex.
Paper files will be kept in locked cabinets.
For statistical analysis, the anonymised data will be
downloaded onto password-protected computers. This
will be accessible by the trial statistician and principal
investigator.
Statistical methods
Available cases will be analysed following intention to
treat principles. The primary outcome will be the BAI
which will be compared from baseline assessment to end
of therapy. A linear mixed model will be used to test
intervention effects, including group comparisons on
mean scores of primary and secondary symptom out-
come measures. Main effects of condition and time (i.e.
repeated measurements) and their interactions will be
examined. Effect sizes will be calculated. Missing data
will be quantified but no imputation will be performed.
A Data Monitoring Committee has not been arranged,
in accordance with the Oxford Clinical Trials Research
Unit and the Medicines for Human Use Clinical Trials
Regulations (2004); because the intervention occurs over
a short period, the protocol will not be modified irre-
spective of data collected during the intervention and
there are minimal risks to participants. No interim ana-
lyses are planned.
The independent Trial Steering Committee will help
monitor safety (including adverse events), assess adher-
ence to the study protocol and the statistical analysis
plan, and oversee progress with data collection.
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Members include the trial statistician, the PI, the trial
consultant clinical psychologist, an independent expert
and a patient representative. The principal investigator
will regularly conduct data audits to check for possible
errors and completeness. If participants or others have
concerns regarding the trial conduct, they are advised to
contact the Patient Advice and Liaison Service at Sussex
Partnership NHS Foundation Trust; this is independent
from the investigator and sponsor.
Patient and public involvement
A Lived Experience Advisory Panel (LEAP) was formed
via Sussex Partnership NHS Trust to engage patients
and public in design of study, design of materials for
ethical approval, and strategies for recruitment and
dissemination.
Adverse events and ethical issues
Adverse events or effects will be monitored throughout
the study. It is possible that a participant may evidence
risk during the assessment or intervention, such as in re-
lation to reported or likely significant harm to them-
selves or others. If so, risk will be assessed by the
psychologists, discussed with the principal investigator
and a supportive plan agreed. This could include inform-
ing the participant’s GP, informing appropriate author-
ities and/or signposting the participant for support
where needed. If a serious adverse event occurs, if
deemed potentially ‘related’ and/or ‘unexpected’ in rela-
tion to the administration of the research procedures,
this will be reported to the research ethics committee
and sponsor in line with ethical approval. The sponsor
(University of Sussex) has appropriate insurance in
place.
Research tests conducted are not for diagnostic pur-
poses, and the examination should not be considered an
alternative to a proper medical consultation. However,
sometimes the joint examination, related assessments
(heart rate and blood pressure) or questionnaires may
suggest a clinically significant issue. If this is the case or
the participant needs further tests, the GP will be con-
tacted in the first instance. The GP will then contact the
participant if further tests are required. If the participant
has any concerns about this, they are invited to contact
a member of research team. The psychologist will make
an assessment of whether a further clinical intervention
is required at the end of therapy, and, if so, refer to the
relevant NHS team for assessment and ongoing
management.
To ensure effective dissemination, results will be pub-
lished in appropriately selected peer-reviewed journals.
Summaries of the findings will be published on the
BSMS website and links provided to publications. This
will aid the dissemination of the research and data, both
to other researchers and interested parties. Participants
will be sent a summary of the research findings if they
consented to this. Fully anonymised data will be made
freely available via an open repository, such as Open Sci-
ence Framework, once the data collection and analyses
are completed.
Changes to method due to COVID-19:
Study assessments will be moved from being completed
at the BSMS campus to online assessment (Qualtrics)
due to COVID-19 quarantine restrictions. Interoception
training will no longer be delivered via MATLAB on
computers at BSMS and rather has been developed as an
app (HeartRater, CELL SOFTWARE). This app will be
installed on a tablet device (Samsung Galaxy Tab A)
which will be posted to participants adhering to govern-
ment safety guidance. Participants will also receive a
pulse oximeter (NONIN), which they will wear whilst it
is connected to the tablet device via USB connection, to
enable their heartbeats to be recorded. Participants will
complete both therapies and interoception training in
their own homes in a private space on a PC, laptop or
smartphone with internet capabilities. Therapy resources
will be shared via Zoom videoconferencing software
using the secure university account and videocalls will
be password protected. All tablet devices will be locked
down using Miradore software to ensure participants
cannot install interfering software, and the study team
can format the tablets remotely if needed. The HeartRa-
ter app data will only be accessible to the study team
and will require a password to access the online data
generated. No personally identifiable information will be
stored with the data collected online. Heart rate mea-
surements will not be collected via a finometer and in-
stead will be observed over videoconference using a
pulse oximeter sent to participants with the tablet.
Discussion
This is the first study to test a targeted intervention for
people with hypermobility and anxiety. The study will
investigate whether ADAPT or EFST are effective in re-
ducing anxiety. The interventions will particularly be
compared in relation to anxiety symptoms, but also in
terms of autonomic trait prediction error, interoceptive
ability, psychiatric disorder, well-being and quality of life
measures. While we expect both interventions will be
beneficial, the results will help determine their relative
effectiveness across the aforementioned outcomes. The
trial will also investigate treatment tolerance for remote
therapy which has been found to be effective in previous
studies in anxiety and depression [48]. An online format
has the potential to increase access to and reduce the
costs of providing evidence-based intervention to those
in need.
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